- cafead Jul 26, 2019 at 11:22: AM
via AbbVie’s latest upbeat read on its Q2 numbers included a sour note that is likely to put another one of Biogen’s top pipeline projects under a cloud.
The pharma giant said today that they shut down a Phase II trial for the anti-tau drug ABBV-8E12 after investigators determined that the data indicated it was useless to push ahead on a neurodegenerative study for progressive supranuclear palsy.
article source
The pharma giant said today that they shut down a Phase II trial for the anti-tau drug ABBV-8E12 after investigators determined that the data indicated it was useless to push ahead on a neurodegenerative study for progressive supranuclear palsy.
article source